HER2-Positive Metastatic Colorectal Cancer (mCRC) | Primary Research (KOL's Insight) | Market Intelligence | Epidemiology & Market Forecast-2035

Metastatic colorectal cancer (mCRC) is still one of the leading causes of cancer-related death, despite significant therapeutic advancements over the previous 20 years. For those with mCRC who were molecularly selected and had the BRAF-V600E mutation along with subpar mismatch repair and significant microsatellite instability, recent developments in targeted therapy have improved the prognosis. According to current projections, CRC will surpass breast cancer as the leading cause of cancer-related death among people aged 20 to 49 by 2040. Currently, CRC is more common in people over 50, is becoming more prevalent in people under 40, and is more likely to occur in men than in women. Even today, in the age of precision medicine, there are still a lot of unmet needs for patients with mCRC.

Description

Despite significant therapeutic advances over the previous 20 years, metastatic colorectal cancer (mCRC) is still one of the leading causes of cancer-related death. For patients with mCRC who were molecularly selected and had the BRAF-V600E mutation along with subpar mismatch repair and significant microsatellite instability, recent developments in targeted therapy have improved the prognosis. Human epidermal growth factor receptor 2 (HER2) gene amplification, which isolates a new subset of mCRC patients, might reveal a novel onco-target in mCRC. According to a status report on the global burden of cancer in 2018, colorectal cancer (CRC) is the second leading cause of death and the third leading cause of incidence. 30 to 40% of CRC patients had metastatic disease at the time of their initial presentation. An HER2 amplified or mutated subpopulation of mCRC was found using functional and genomic analyses of patient-derived xenografts. Only about 3% of CRC patients have HER2 amplification.

HER2-Positive Metastatic Colorectal Cancer (mCRC) (Epidemiology)

The second most common cause of cancer-related death in the general population and the third most common cause of cancer-related death in both men and women in the United States is colorectal cancer (CRC). According to current projections, CRC will surpass breast cancer as the leading cause of cancer-related death among people aged 20 to 49 by 2040. Currently, CRC is more common in people over 50, is becoming more prevalent in people under 40, and is more likely to occur in men than in women.

HER2-Positive Metastatic Colorectal Cancer (mCRC) -Current Market Size & Forecast Trends

The market for HER2-positive metastatic colorectal cancer (mCRC) is projected to grow significantly, with an estimated value of approximately USD 3.4 billion in 2022, expected to reach around USD 4.8 billion by 2030, reflecting a compound annual growth rate (CAGR) of 4.6% during the forecast period from 2023 to 2030. The growth is driven by increasing incidence rates of colorectal cancer, advancements in targeted therapies such as tucatinib and trastuzumab, which received accelerated FDA approval for HER2-positive mCRC, and ongoing research into new treatment options. The introduction of novel therapies like trastuzumab deruxtecan, currently in clinical trials for HER2-expressing mCRC, further supports market expansion. North America is anticipated to hold a significant share of the market due to its advanced healthcare infrastructure and high prevalence of colorectal cancer. Overall, the HER2-positive mCRC market is well-positioned for robust growth through 2035, bolstered by the continuous development of innovative therapies and increasing patient awareness.

Even today, in the age of precision medicine, there are still a lot of unmet needs for patients with mCRC. Rarely occurring carcinogenic genetic mutations like APC, TP53, and RAS, as well as the HER2 actionable targets, have typically remained resistant to therapy up to this point. Consensus Molecular Subtype, or CMS, has emerged as a prognostic or predictive marker of targeted therapy, but more study is required to categorize subtypes more precisely across various platforms and clinical contexts. The identification and confirmation of new viable targets may be aided by ongoing initiatives to exchange and combine clinical and genetic data. For mCRC cases without druggable targets, target blockage and ICI combinations may provide treatment options. Our comprehension of the specific mechanism of action and resistance of targeted treatments would also improve as a result of our increased knowledge of cancer biology, which also includes details about the microenvironment and heterogeneity. This knowledge would also help us improve the current methods for treating mCRC. S095029 (Symphogen), Trastuzumab deruxtecan (AstraZeneca/Daiichi Sankyo), Tislelizumab (BeiGene), Zanidatamab (Zymeworks), and other key players are in the clinical stages of development and have the potential to drive the market in an upward trend.

Report Highlights

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Current Market Trends

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Current & Forecasted Cases across the G8 Countries

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Market Opportunities and Sales Potential for Agents

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Patient-based Market Forecast to 2035

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Untapped Business Opportunities

HER2-Positive Metastatic Colorectal Cancer (mCRC) - Product Positioning Vis-a-vis Competitors' Products

HER2-Positive Metastatic Colorectal Cancer (mCRC) - KOLs Insight